+
+
Stay Informed
STRUCTURAL INTERVENTIONS

AMPLATZER™ TALISMAN™
PFO OCCLUDER CLINICAL DATA

Effective PFO closure is made easier with the Amplatzer Talisman PFO Occluder.5 For patients who have experienced a PFO-associated stroke, clinical trials have shown that they can benefit from PFO closure.1-3 This minimally-invasive procedure significantly reduces the risk of recurrent ischemic stroke and offers an excellent safety profile.

THE LANDMARK RESPECT TRIAL1

Still the definitive clinical trial on PFO closure

Study Design

The RESPECT trial is the largest trial ever conducted on PFO closure. This trial studied the Amplatzer™ PFO Occluder, on which the new Amplatzer Talisman device is based.

It stands apart from other PFO closure studies since it's the largest clinical trial with the most extensive follow-up, spanning 13 years. The 980 enrolled patients were followed for a median of 5.9 years. Researchers ultimately collected 5,810 patient-years of data—almost 2 times more than other PFO trials.

The trial was conducted at 69 centers across the U.S. and Canada and included patients on anticoagulation therapy – a real-world cross-section of patients – unlike other PFO trials, REDUCE2 and CLOSE3.
 

The Findings

The RESPECT trial offers conclusive evidence that using the Amplatzer PFO Occluder to close the PFO in patients with a PFO-associated stroke is more beneficial than medical therapy alone, reducing the risk of another stroke.

A meta-analysis on three randomized controlled trials on PFO

A meta-analysis on three randomized controlled trials on PFO closure confirmed that..."PFO closure was superior to medical therapy for secondary prevention of stroke…with a more robust benefit when the Amplatzer PFO Occluder...was used.”4

Summary of Findings

Excellent Procedural Results 

The RESPECT trial data reveal high rates of technical and procedural success and excellent closure with the study’s highly stringent criteria. At only 6 months, most patients also demonstrated freedom from shunt — both at rest and during Valsalva.1

99.1%

TECHNICAL SUCCESS*

96.1%

PROCEDURAL SUCCESS†

94.2%

EFFECTIVE CLOSURE
(N ≤ 9 BUBBLES)

Excellent Safety1

0%

DEVICE EMBOLIZATION

0%

DEVICE EROSION

0%

DEVICE THROMBUS

Note: Rates are calculated based on data in final publication.
*Successful delivery and release of the device at the time of first procedure for subjects in whom a study device was attempted.
†Successful implant at the time of the first procedure with no reported in-hospital serious adverse events.

  • Significantly lower risk of recurrent stroke

    The RESPECT trial revealed a 62% relative risk reduction for recurrent cryptogenic ischemic stroke with the Amplatzer PFO Occluder vs medical therapy.1
     

    Significantly lower risk of recurrent stroke

    The trial showed there was a 45% relative risk reduction for any recurrent ischemic stroke over nearly 6 years of follow-up, compared to medical therapy.1
     

    Significantly lower risk of recurrent stroke
  • Low Rates of Atrial Fibrillation

    The RESPECT trial also revealed low rates of serious atrial fibrillation (AF) with the Amplatzer device, consistent with medical therapy.1 AF rates were somewhat higher in the REDUCE trial,2 which used a different PFO closure device.
     

    RATE

    (PER 100 PATIENT YEARS)

    		RESPECT6REDUCE2
    Serious AF /Flutter*0.220.65
    Any AF/Flutter0.761.90

    *In RESPECT, serious AF/Flutter was adjudicated by an independent board of physicians. In REDUCE, it was determined by the local investigator.

MAT-2202031 v2.0 | Item approved for OUS use only.

References
  1. Saver JL, Carroll JD, Thaler DE, et al. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med. 2017;377:1022-1032. doi: 10.1056/NEJMoa1610057.
  2. Søndergaard L, Kasner SE, Rhodes JF, et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med. 2017;377:1033-1042. doi: 10.1056/NEJMoa1707404.
  3. Mas J-L, Derumeaux G, Guillon B, et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med. 2017;377:1011-1021 and supplementary appendix. doi: 10.1056/NEJMoa1705915.
  4. Mojadidi MK, Zaman MO, Elgendy IY, et al. Cryptogenic stroke and patent foramen ovale. J Am Coll Cardiol. 2018;71(9):1035-1043. doi: 10.1016/j.jacc.2017.12.059.
  5. Tests performed by and data on file at Abbott.
  6. Amplatzer™ Talisman™ PFO Occluder Instructions For Use.
Abbott Logo

Follow Abbott

Copyright © 2024 Abbott, 3200 Lakeside Dr, Santa Clara, 95054, U.S.A.
Caution: Product(s) are intended for use by or under the direction of a physician. Prior to use, reference to the Instructions for Use, inside the product carton (when available) or at www.eifu.abbott for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.
Illustrations are artist’s representations only and should not be considered as engineering drawings or photographs. Photos on file at Abbott.
Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates.
No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

MAT-2000631 v18.0 | Item approved for OUS use only.

YOU ARE ABOUT TO ENTER AN ABBOTT COUNTRY OR REGION SPECIFIC WEBSITE.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of the product that are not approved in other countries or regions.

U.S. Health Care Professionals International Health Care Professionals

YOU ARE ABOUT TO LEAVE
www.structural­heart.abbott

You are now leaving www.structuralheart.abbott. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.

OkCancel
+